Evidence map›Paper›PMID 28760741›Full record

ArticleThe British journal of general practice : the journal of the Royal College of General Practitioners2017

Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis.

Peter Ueda, Thomas Wai-Chun Lung, Philip Clarke, Goodarz Danaei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of general practice : the journal of the Royal College of General Practitioners, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Statin Therapy in Very Old Patients: Lights and Shadows.Frontiers in cardiovascular medicine · 2021
    Review
  5. Article
  6. Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort.The British journal of general practice : the journal of the Royal College of General Practitioners · 2019
    Article
  7. Article
  8. 2014 NICE cholesterol guidelines.The British journal of general practice : the journal of the Royal College of General Practitioners · 2017
    Article
  9. The polypharmacy challenge: time for a new script?The British journal of general practice : the journal of the Royal College of General Practitioners · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Peter UedaDepartment of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, US, Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, and Department of Global Health Policy, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Thomas Wai-Chun LungHealth Economics and Process Evaluation, the George Institute for Global Health, University of New South Wales, Australia.
Philip ClarkeCentre for Health Policy, School of Population and Global Health, University of Melbourne, Carlton, Victoria, Australia.
Goodarz DanaeiDepartment of Global Health and Population, and Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, US.

Funding

Reducing disparities in diabetes through expanded insurance coverage.R01DK090435 · NIDDK · HARVARD SCHOOL OF PUBLIC HEALTH · PI DANAEI, GOODARZ · 2011 to 2014
$1.8M
NIDDK NIH HHS R01 DK090435
6 · The paper itself

Abstract

backgroundThe 2014 guidelines on cardiovascular risk assessment and lipid modification from the National Institute for Health and Care Excellence (NICE) recommend statin therapy for adults with prevalent cardiovascular disease (CVD), and for adults with a 10-year CVD risk of ≥10%, estimated using the QRISK2 algorithm.

aimTo determine risk factor levels required to exceed the risk threshold for statin therapy, and to estimate the number of adults in England who would require statin therapy under the guidelines. DESIGN AND

settingCross-sectional study using a sample representative of the English population aged 30-84 years.

methodTo estimate 10-year CVD risk different combinations of risk factor levels were entered into the QRISK2 algorithm. The NICE guidelines were applied to the sample using data from the Health Survey for England 2011.

resultsEven with optimal risk factor levels, males of different ethnicities would exceed the 10% risk threshold between the ages of 60 and 70 years, and females would exceed the threshold between 65 and 75 years. Under the NICE guidelines, 11.8 million males and females (37% of the adults aged 30-84 years) would require statin therapy, most of them (9.8 million) for primary prevention. When analysed by age, 95% of males and 66% of females without CVD in ages 60-74 years, including all males and females in ages 75-84 years, would require statin therapy.

conclusionUnder the 2014 NICE guidelines, 11.8 million (37%) adults in England aged 30-84 years, including almost all males >60 years in all females >75 years, require statin therapy.

Indexed as

Cardiovascular DiseasesPractice Guidelines as TopicPrimary PreventionAdultAgedAged, 80 and overAge FactorsAlgorithmsCross-Sectional StudiesEnglandFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedHydroxymethylglutaryl-CoA Reductase Inhibitorscardiovascular diseasegeneral practiceHMG-CoA reductase inhibitorspreventionriskstatins

Identifiers

PMID28760741
PMCPMC5569739

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.